647 related articles for article (PubMed ID: 15201783)
1. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study.
Giannantoni A; Di Stasi SM; Stephen RL; Bini V; Costantini E; Porena M
J Urol; 2004 Jul; 172(1):240-3. PubMed ID: 15201783
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of intravesical resiniferatoxin for anticholinergic treatment refractory detrusor overactivity due to nonspinal cord lesions.
Kuo HC
J Urol; 2003 Sep; 170(3):835-9. PubMed ID: 12913711
[TBL] [Abstract][Full Text] [Related]
3. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
Giannantoni A; Mearini E; Del Zingaro M; Porena M
Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic options for refractory neurogenic detrusor overactivity.
Giannantoni A; Mearini E; Di Stasi SM; Costantini E; Zucchi A; Mearini L; Fornetti P; Del Zingaro M; Navarra P; Porena M
Minerva Urol Nefrol; 2004 Mar; 56(1):79-87. PubMed ID: 15195033
[TBL] [Abstract][Full Text] [Related]
5. Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study.
Giannantoni A; Di Stasi SM; Stephen RL; Navarra P; Scivoletto G; Mearini E; Porena M
J Urol; 2002 Apr; 167(4):1710-4. PubMed ID: 11912393
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
[TBL] [Abstract][Full Text] [Related]
7. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity.
Karsenty G; Reitz A; Lindemann G; Boy S; Schurch B
Urology; 2006 Dec; 68(6):1193-7. PubMed ID: 17141831
[TBL] [Abstract][Full Text] [Related]
8. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity.
Giannantoni A; Di Stasi SM; Nardicchi V; Zucchi A; Macchioni L; Bini V; Goracci G; Porena M
J Urol; 2006 Jun; 175(6):2341-4. PubMed ID: 16697870
[TBL] [Abstract][Full Text] [Related]
9. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents.
Kuo HC
Urology; 2004 May; 63(5):868-72. PubMed ID: 15134967
[TBL] [Abstract][Full Text] [Related]
10. Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
Gamé X; Castel-Lacanal E; Bentaleb Y; Thiry-Escudié I; De Boissezon X; Malavaud B; Marque P; Rischmann P
Eur Urol; 2008 Mar; 53(3):613-8. PubMed ID: 17804150
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction.
Pannek J; Göcking K; Bersch U
BJU Int; 2009 Nov; 104(9):1246-50. PubMed ID: 19426192
[TBL] [Abstract][Full Text] [Related]
12. Refractory neurogenic detrusor overactivity.
Cruz F; Silva C
Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
[TBL] [Abstract][Full Text] [Related]
14. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
[TBL] [Abstract][Full Text] [Related]
15. Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity?
Kessler TM; Danuser H; Schumacher M; Studer UE; Burkhard FC
Neurourol Urodyn; 2005; 24(3):231-6. PubMed ID: 15747344
[TBL] [Abstract][Full Text] [Related]
16. Do repeat intradetrusor botulinum toxin type a injections yield valuable results? Clinical and urodynamic results after five injections in patients with neurogenic detrusor overactivity.
Reitz A; Denys P; Fermanian C; Schurch B; Comperat E; Chartier-Kastler E
Eur Urol; 2007 Dec; 52(6):1729-35. PubMed ID: 17884281
[TBL] [Abstract][Full Text] [Related]
17. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
[TBL] [Abstract][Full Text] [Related]
18. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.
Rajkumar GN; Small DR; Mustafa AW; Conn G
BJU Int; 2005 Oct; 96(6):848-52. PubMed ID: 16153215
[TBL] [Abstract][Full Text] [Related]
19. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type a in overactive neurogenic bladder.
Haferkamp A; Schurch B; Reitz A; Krengel U; Grosse J; Kramer G; Schumacher S; Bastian PJ; Büttner R; Müller SC; Stöhrer M
Eur Urol; 2004 Dec; 46(6):784-91. PubMed ID: 15548448
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of suburothelial injection of botulinum a toxin for neurogenic detrusor overactivity due to chronic cerebrovascular accident and spinal cord lesions.
Kuo HC
Urology; 2006 Feb; 67(2):232-6. PubMed ID: 16442605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
